DK2155255T3 - Sammensætninger der omfatter en hydrofob forbindelse og et polyaminosyrekonjugat - Google Patents

Sammensætninger der omfatter en hydrofob forbindelse og et polyaminosyrekonjugat

Info

Publication number
DK2155255T3
DK2155255T3 DK08795840.1T DK08795840T DK2155255T3 DK 2155255 T3 DK2155255 T3 DK 2155255T3 DK 08795840 T DK08795840 T DK 08795840T DK 2155255 T3 DK2155255 T3 DK 2155255T3
Authority
DK
Denmark
Prior art keywords
compositions
polyamino acid
hydrophobic compound
acid conjugate
conjugate
Prior art date
Application number
DK08795840.1T
Other languages
English (en)
Inventor
Yucheng Song
Sang Van
Xinghe Wang
Zheng Hou
Zhongling Feng
Gang Zhao
Lei Yu
Original Assignee
Nitto Denko Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Denko Corp filed Critical Nitto Denko Corp
Application granted granted Critical
Publication of DK2155255T3 publication Critical patent/DK2155255T3/da

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/146—Peptides, e.g. proteins the peptide being a polyamino acid, e.g. poly-lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Radiology & Medical Imaging (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK08795840.1T 2007-05-09 2008-05-08 Sammensætninger der omfatter en hydrofob forbindelse og et polyaminosyrekonjugat DK2155255T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91690307P 2007-05-09 2007-05-09
PCT/US2008/063114 WO2008141107A2 (en) 2007-05-09 2008-05-08 Compositions that include a hydrophobic compound and a polyamino acid conjugate

Publications (1)

Publication Number Publication Date
DK2155255T3 true DK2155255T3 (da) 2013-09-02

Family

ID=39864977

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08795840.1T DK2155255T3 (da) 2007-05-09 2008-05-08 Sammensætninger der omfatter en hydrofob forbindelse og et polyaminosyrekonjugat

Country Status (11)

Country Link
US (2) US8197828B2 (da)
EP (1) EP2155255B1 (da)
JP (1) JP5341879B2 (da)
KR (1) KR20100017540A (da)
CN (1) CN101678123B (da)
CA (1) CA2683590A1 (da)
DK (1) DK2155255T3 (da)
ES (1) ES2430380T3 (da)
PT (1) PT2155255E (da)
TW (1) TW200902070A (da)
WO (1) WO2008141107A2 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2631704A1 (en) 2005-12-05 2007-06-14 Nitto Denko Corporation Polyglutamate-amino acid conjugates and methods
CA2683590A1 (en) 2007-05-09 2008-11-20 Nitto Denko Corporation Compositions that include a hydrophobic compound and a polyamino acid conjugate
JP2012505906A (ja) * 2008-10-15 2012-03-08 日東電工株式会社 ポリグルタメートコンジュゲートの調製方法
JP2013514443A (ja) * 2009-12-16 2013-04-25 日東電工株式会社 ポリグルタミン酸の制御された合成
JP6262201B2 (ja) * 2012-04-12 2018-01-17 日東電工株式会社 コポリマー結合体
ES2633765T3 (es) * 2012-05-07 2017-09-25 Nitto Denko Corporation Conjugados poliméricos con un ligador
KR101494639B1 (ko) * 2013-05-15 2015-02-23 고려대학교 산학협력단 엽산 Cy7계 치료진단용 약물 전달 시스템 및 이것의 제조방법
AU2014390729B2 (en) 2014-04-07 2018-11-29 Nitto Denko Corporation Novel polymer-based hydrotropes for hydrophobic drug delivery

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59186924A (ja) * 1983-04-08 1984-10-23 Kureha Chem Ind Co Ltd ヒト免疫グロブリン結合抗腫瘍剤
ATE26584T1 (de) * 1983-07-01 1987-05-15 Battelle Memorial Institute In-vivo abbaubares polypeptid und dessen anwendung zur verzoegerten freigabe von medikamenten.
US5385738A (en) * 1983-10-14 1995-01-31 Sumitomo Pharmaceuticals Company, Ltd. Sustained-release injection
ATE60340T1 (de) * 1984-10-19 1991-02-15 Battelle Memorial Institute Durch mikroorganismen abbaubares polypeptid und seine verwendung fuer die fortschreitende abgabe von medikamenten.
CS254355B1 (en) * 1985-04-10 1988-01-15 Vladimir Saudek Soluble and biodegradatable copolymeres activated for bond of biologicaly active substances
CH667874A5 (fr) * 1985-12-19 1988-11-15 Battelle Memorial Institute Polypeptide synthetique biodegradable et son utilisation pour la preparation de medicaments.
US6673347B1 (en) * 1986-04-30 2004-01-06 Gryphon Therapeutics Polypeptide and protein derivatives and process for their preparation
US5102652A (en) 1986-07-03 1992-04-07 Advanced Magnetics Inc. Low molecular weight carbohydrates as additives to stabilize metal oxide compositions
IN165717B (da) * 1986-08-07 1989-12-23 Battelle Memorial Institute
AU614465B2 (en) * 1989-04-05 1991-08-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Medicinal emulsions
JP2517760B2 (ja) * 1989-05-11 1996-07-24 新技術事業団 水溶性高分子化医薬製剤
US5580575A (en) * 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
DE69131721T2 (de) 1990-04-10 2000-03-02 Imarx Pharmaceutical Corp., Tucson Polymere als Kontrastmittel bei magnetischer Resonanz
US6517824B1 (en) * 1990-05-14 2003-02-11 University Of Medicine & Denistry Of New Jersey Polymer compositions comprising antifibrotic agents, and methods of treatment, pharmaceutical compositions, and methods of preparation therefor
US5372807A (en) 1990-05-14 1994-12-13 University Of Medicine And Dentistry Of New Jersey Polymers containing antifibrotic agents, compositions containing such polymers, and methods of preparation and use
US5660822A (en) 1990-05-14 1997-08-26 University Of Medicine & Dentistry Of N.J. Polymers containing antifibrotic agents, compositions containing such polymers, and methods of preparation and use
US5219564A (en) 1990-07-06 1993-06-15 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
US6762188B1 (en) * 1990-06-19 2004-07-13 Smithkline Beecham Corporation Pharmaceutically active benzoquinazoline compounds
GB9013615D0 (en) * 1990-06-19 1990-08-08 Wellcome Found Pharmaceutical compounds
DE4115789A1 (de) * 1991-05-10 1992-11-12 Schering Ag Makrocyclische polymer-komplexbildner, deren komplexe, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
GB9120653D0 (en) * 1991-09-27 1991-11-06 Procter & Gamble Dispensing agent
US5384333A (en) * 1992-03-17 1995-01-24 University Of Miami Biodegradable injectable drug delivery polymer
KR940003548U (ko) * 1992-08-14 1994-02-21 김형술 세탁물 건조기
US5871710A (en) * 1992-09-04 1999-02-16 The General Hospital Corporation Graft co-polymer adducts of platinum (II) compounds
US6004763A (en) 1992-09-11 1999-12-21 Institut Pasteur Antigen-carrying microparticles and their use in the induction of humoral or cellular responses
FR2695563B1 (fr) * 1992-09-11 1994-12-02 Pasteur Institut Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
NZ262679A (en) 1993-02-22 1997-08-22 Vivorx Pharmaceuticals Inc Compositions for in vivo delivery of pharmaceutical agents where the agents are contained in a polymeric shell
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US5548064A (en) * 1993-05-24 1996-08-20 Biotech Australia Pty Limited Vitamin B12 conjugates with EPO, analogues thereof and pharmaceutical compositions
US5449720A (en) * 1993-05-24 1995-09-12 Biotech Australia Pty Limited Amplification of the VB12 uptake system using polymers
GB2282384B8 (en) * 1993-08-18 1997-09-04 Europ Economic Community Drug delivery agents incorporating mitomycin
US6441026B1 (en) * 1993-11-08 2002-08-27 Aventis Pharma S.A. Antitumor compositions containing taxane derivatives
US5980862A (en) * 1995-06-02 1999-11-09 Research Corporation Technologies Magnetic resonance imaging agents for the detection of physiological agents
US6713045B1 (en) * 1995-06-02 2004-03-30 Research Corporation Technologies, Inc. Targeted magnetic resonance imaging agents for the detection of physiological processes
US5762909A (en) * 1995-08-31 1998-06-09 General Electric Company Tumor targeting with polymeric molecules having extended conformation
DE19548114C2 (de) * 1995-12-21 2000-04-27 Deutsches Krebsforsch Konjugat, umfassend einen Wirkstoff, ein Polypeptid und einen Polyether
US6441025B2 (en) 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
CN1304058C (zh) * 1996-03-12 2007-03-14 Pg－Txl有限公司 水溶性紫杉醇产品
US6030941A (en) * 1996-05-01 2000-02-29 Avi Biopharma, Inc. Polymer composition for delivering substances in living organisms
US5929198A (en) * 1996-07-16 1999-07-27 Nalco Chemical Company Biodegradable poly (amino acid)s, derivatized amino acid polymers and methods for making same
US5900228A (en) * 1996-07-31 1999-05-04 California Institute Of Technology Bifunctional detection agents having a polymer covalently linked to an MRI agent and an optical dye
US6251866B1 (en) * 1997-08-05 2001-06-26 Watson Laboratories, Inc. Conjugates targeted to the interleukin-2 receptor
US6229009B1 (en) * 1997-08-29 2001-05-08 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Polycarboxylic based cross-linked copolymers
US6528061B1 (en) * 1997-09-04 2003-03-04 Pasteur Institut Immunogenic polypeptides that mimic a surface polysaccharide antigen of a pathogenic microorganism, method for obtaining the same, and their use in vaccine compositions
JP3390965B2 (ja) * 1997-09-12 2003-03-31 理化学研究所 糖結合スフィンゴシンを含有するポリマー化合物
US6391336B1 (en) * 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
US20040170563A1 (en) * 1997-10-27 2004-09-02 Meade Thomas J. Magnetic resonance imaging agents for the delivery of therapeutic agents
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US5981564A (en) 1998-07-01 1999-11-09 Universite Laval Water-soluble derivatives of paclitaxel, method for producing same and uses thereof
US20030124143A1 (en) * 1998-08-31 2003-07-03 Armelle Phalipon Methods for selecting immunogenic polypeptides
US6143817A (en) * 1998-10-07 2000-11-07 National Starch & Chemical Co. Use of derivatives of polyamino acids as emulsifiers stabilizers in aqueous free radical emulsion polymerization
AU1688099A (en) * 1998-12-24 2000-07-31 Kyowa Hakko Kogyo Co. Ltd. Pharmaceutical preparation
EP1031354A3 (en) 1999-01-19 2003-02-05 Rohm And Haas Company Polymeric MRI Contrast agents
US6716452B1 (en) * 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US20040121954A1 (en) * 1999-04-13 2004-06-24 Xu Wuhan Jingya Poly(dipeptide) as a drug carrier
US20010041189A1 (en) * 1999-04-13 2001-11-15 Jingya Xu Poly(dipeptide) as a drug carrier
US6326021B1 (en) 1999-06-18 2001-12-04 The Ohio State University Research Foundation Biocompatible polymeric delivery systems having functional groups attached to the surface thereof
US20030054977A1 (en) * 1999-10-12 2003-03-20 Cell Therapeutics, Inc. Manufacture of polyglutamate-therapeutic agent conjugates
BRPI0014652B1 (pt) 1999-10-12 2016-08-09 Cell Therapeutics Inc fabricação de conjugados de agente terapêutico-poliglutamato
US6136846A (en) 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
US6685915B2 (en) * 1999-12-01 2004-02-03 General Electric Company Extended-linear polymeric contrast agents, and synthesizing methods, for medical imaging
US6235264B1 (en) * 1999-12-01 2001-05-22 General Electric Company Medical imaging method for characterizing tumor angiogenesis using polymeric contrast agents
US20020183243A1 (en) 2000-03-17 2002-12-05 Cell Therapeutics, Inc. Polyglutamic acid-camptothecin conjugates and methods of preparation
US20020077290A1 (en) * 2000-03-17 2002-06-20 Rama Bhatt Polyglutamic acid-camptothecin conjugates and methods of preparation
HUP0204562A2 (hu) * 2000-03-17 2003-04-28 Cell Therapeutics, Inc. Poliglutaminsav-kamptotecin konjugátumok, eljárás előállításukra és ilyen konjugátumokat tartalmazó gyógyászati készítmények
JP2001288097A (ja) 2000-04-07 2001-10-16 Pg-Txl Co Lp 水溶性パクリタキセル誘導体
JP2004501875A (ja) 2000-06-14 2004-01-22 メダレックス，インコーポレイティド トリペプチドプロドラッグ化合物
GB0018240D0 (en) * 2000-07-25 2000-09-13 Pharmacia & Upjohn Spa Polymeric conjugates of antitumor agents
DE60121016T2 (de) * 2000-09-26 2006-12-21 Toudai Tlo, Ltd. Polymere mizelle mit darin eingeschlossenem cisplatin und ihre verwendung
WO2002026867A2 (en) * 2000-09-29 2002-04-04 The Regents Of The University Of California Dendrimeric support or carrier macromolecule
US6497901B1 (en) 2000-11-02 2002-12-24 Royer Biomedical, Inc. Resorbable matrices for delivery of bioactive compounds
US7070797B2 (en) * 2000-11-07 2006-07-04 Dana Farber Cancer Institute, Inc. Method of treating hematologic tumors and cancers
US6916492B2 (en) 2001-03-30 2005-07-12 Council Of Scientific & Industrial Research Natural nontoxic multicolor fluorescent protein dye from a marine invertebrate, compositions containing the said dye and its uses
EP1610751A4 (en) 2001-04-26 2006-05-24 Univ Texas THERAPEUTIC AGENT / LIGAND CONJUGATE COMPOSITIONS, ITS SYNTHESIS PROCESSES AND ITS APPLICATION
EP1408066B1 (en) * 2001-06-20 2010-03-31 Nippon Kayaku Kabushiki Kaisha Block copolymer reduced in impurity content; polymeric carrier; pharmaceutical preparations in polymeric form and process for the preparation of the same
US20040043030A1 (en) * 2001-07-31 2004-03-04 Immunomedics, Inc. Polymeric delivery systems
US20030049253A1 (en) * 2001-08-08 2003-03-13 Li Frank Q. Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines
EP1450844A4 (en) 2001-11-09 2009-07-29 Enzon Inc POLYMER THIOL-LINKED PRODRUGS USING BENZYL ELIMINATION SYSTEMS
US7261875B2 (en) 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
US6939538B2 (en) * 2002-04-11 2005-09-06 Biomedical Research Models, Inc. Extended release analgesic for pain control
JP2004018494A (ja) * 2002-06-19 2004-01-22 Japan Science & Technology Corp ブロック共重合体−薬剤複合体の製造法
US20040047835A1 (en) * 2002-09-06 2004-03-11 Cell Therapeutics, Inc. Combinatorial drug therapy using polymer drug conjugates
FR2844514B1 (fr) * 2002-09-16 2007-10-19 Neovacs Produit immunogene stable comprenant des heterocomplexes antigeniques, compositions les contenant et procede de preparation
AU2003280592B2 (en) 2002-10-31 2008-12-18 Nippon Kayaku Kabushiki Kaisha High-molecular weight derivatives of camptothecins
CA2527665A1 (en) * 2003-05-30 2004-12-16 Centocor, Inc. Formation of novel erythropoietin conjugates using transglutaminase
US6855695B2 (en) 2003-06-13 2005-02-15 Vion Pharmaceuticals, Inc. Water-soluble SHPs as novel alkylating agents
US20050187147A1 (en) 2003-09-22 2005-08-25 Newman Michael J. Compositions and methods for increasing drug efficiency
US20050118718A1 (en) 2003-09-22 2005-06-02 University Of Utah Research Foundation Stabilization and controlled delivery of ionic biopharmaceuticals
ATE458022T1 (de) 2003-12-10 2010-03-15 Toudai Tlo Ltd Koordinationskomplex von diaminocyclohexanplatin(ii) mit einem blockcopolymer mit einem poly(carbonsäure)segment und diesen enthaltendes antitumormittel
US20050152842A1 (en) * 2003-12-24 2005-07-14 Chun Li Poly (L-glutamic acid) paramagnetic material complex and use as a biodegradable MRI contrast agent
WO2005079861A2 (en) * 2004-02-13 2005-09-01 Safeway Investments Ltd. Polymeric water soluble prodrugs
US20050266067A1 (en) 2004-03-02 2005-12-01 Shiladitya Sengupta Nanocell drug delivery system
US7317070B1 (en) * 2004-03-12 2008-01-08 Sigma-Aldrich Co. Process for the preparation of polyamino acids
KR20050104152A (ko) 2004-04-28 2005-11-02 최승호 경구용 약물의 흡수를 증진하는 약제학적 조성물
US20050271585A1 (en) 2004-06-07 2005-12-08 General Electric Company Extended conjugated polymers
US20050276783A1 (en) 2004-06-10 2005-12-15 Ernest Giralt Lledo Polypeptides with the capacity to entrap drugs and release them in a controlled way
TW200616604A (en) * 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
US7282194B2 (en) * 2004-10-05 2007-10-16 Gp Medical, Inc. Nanoparticles for protein drug delivery
WO2006041613A2 (en) * 2004-10-05 2006-04-20 Nanomega Medical Corporation Nanoparticles for targeting hepatoma cells
CA2631704A1 (en) * 2005-12-05 2007-06-14 Nitto Denko Corporation Polyglutamate-amino acid conjugates and methods
US20080051603A1 (en) 2006-06-15 2008-02-28 Cell Therapeutics, Inc. Process for the preparation of poly-alpha-glutamic acid and derivatives thereof
US20080181852A1 (en) * 2007-01-29 2008-07-31 Nitto Denko Corporation Multi-functional Drug Carriers
CN101674852A (zh) * 2007-04-10 2010-03-17 日东电工株式会社 多功能聚谷氨酸盐药物载体
JP2010528122A (ja) * 2007-05-09 2010-08-19 日東電工株式会社 白金薬剤と結合されたポリマー
CA2683590A1 (en) 2007-05-09 2008-11-20 Nitto Denko Corporation Compositions that include a hydrophobic compound and a polyamino acid conjugate
CN101707869A (zh) * 2007-05-09 2010-05-12 日东电工株式会社 具有多种药物的聚谷氨酸盐结合物和聚谷氨酸盐-氨基酸结合物
WO2009111271A1 (en) * 2008-03-06 2009-09-11 Nitto Denko Corporation Polymer paclitaxel conjugates and methods for treating cancer
JP2012505906A (ja) * 2008-10-15 2012-03-08 日東電工株式会社 ポリグルタメートコンジュゲートの調製方法
JP2013514443A (ja) 2009-12-16 2013-04-25 日東電工株式会社 ポリグルタミン酸の制御された合成
BR112012022337A2 (pt) 2010-03-11 2016-07-05 Nitto Denko Corp composição e respectivos método de preparação e uso de quantidade eficaz
US20120052015A1 (en) 2010-08-26 2012-03-01 Nitto Denko Corporation End-capped polymers

Also Published As

Publication number Publication date
PT2155255E (pt) 2013-10-15
US8197828B2 (en) 2012-06-12
ES2430380T3 (es) 2013-11-20
TW200902070A (en) 2009-01-16
JP5341879B2 (ja) 2013-11-13
WO2008141107A2 (en) 2008-11-20
CN101678123B (zh) 2014-07-16
WO2008141107A8 (en) 2009-06-18
WO2008141107A3 (en) 2009-04-23
EP2155255A2 (en) 2010-02-24
CA2683590A1 (en) 2008-11-20
CN101678123A (zh) 2010-03-24
US8329199B2 (en) 2012-12-11
EP2155255B1 (en) 2013-08-14
JP2010526829A (ja) 2010-08-05
US20120230917A1 (en) 2012-09-13
KR20100017540A (ko) 2010-02-16
US20080279777A1 (en) 2008-11-13

Similar Documents

Publication Publication Date Title
FR19C1035I2 (fr) Compositions fungicidal
DK2277509T3 (da) DPP IV inhibitorformuleringer
PL2123158T3 (pl) Kompozycja chwastobójcza
ITMI20062368A1 (it) Composizioni erbicide
PT2097111E (pt) Heterodímeros de ácido glutámico
BRPI0811926A2 (pt) Composições herbicidas
BRPI1008313A2 (pt) "conector modular"
BRPI0720216A2 (pt) Composições microbicidas
NO20090578A (no) Farmasøytisk sammensetning inneholdende en tetrahydrofolsyre
BRPI0820381A2 (pt) Formulações farmacêuticas
RU2493831C3 (ru) Фармацевтические композиции
DK2155255T3 (da) Sammensætninger der omfatter en hydrofob forbindelse og et polyaminosyrekonjugat
BRPI0814188A2 (pt) Formulações
DE102007041169B8 (de) Flugkorbball
EP2047820A4 (en) ORTHODONTIC FASTENING BRIDGE
BRPI0810660A2 (pt) Derivados do ácido lipóico
BRPI0807185A2 (pt) Musse
BRPI0815652A2 (pt) Composições herbicidas
DK2097068T3 (da) Formuleringer af peg-interferon-alpha-konjugater
EP2162954A4 (en) Modular connector
BRPI0820198A2 (pt) composições farmacêuticas
DE602007012490D1 (de) Herbizidzusammensetzung
BR112012014449A2 (pt) composições biocidas que compreendem derivados do ácido piroglutâmico
ATE431137T1 (de) Fexofenadinlösungsformulierung
BRPI0810790A2 (pt) Formulações de aminoácidos n-halogenados